Boris K. Lin
Impact in
- Hematology top 0.2%
- Multiple Myeloma Research and Treatments
- Oncology top 2%
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
Papers in
-
- PI3K/AKT/mTOR signaling in cancer 7
- Protein Degradation and Inhibitors 4
- Oncology 21
- Peptidase Inhibition and Analysis 7
- Co-authors
- Kenneth C. Anderson (16 shared papers)Teru Hideshima (14 shared papers)Dharminder Chauhan (14 shared papers)Yu‐Tzu Tai (13 shared papers)Faith E. Davies (6 shared papers)Klaus Podar (13 shared papers)Paul G. Richardson (6 shared papers)Noopur Raje (4 shared papers)
- Journals
- Blood (15 papers)Journal of Clinical Oncology (9 papers)Leukemia (2 papers)Experimental Hematology (2 papers)Molecular and Cellular Biology (2 papers)
- Partner nations
- United StatesGermanyUnited Kingdom
In The Last Decade
Boris K. Lin
48 papers receiving 4.3k citations
Hit Papers
Peers
Comparison fields: 5 of 113
- Hematology 2.4k
- Oncology 1.6k
- Genetics 543
- Molecular Biology 2.8k
- Pathology and Forensic Medicine 505
Countries citing papers authored by Boris K. Lin
This map shows the geographic impact of Boris K. Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Boris K. Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Boris K. Lin more than expected).
Fields of papers citing papers by Boris K. Lin
This network shows the impact of papers produced by Boris K. Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Boris K. Lin. The network helps show where Boris K. Lin may publish in the future.
Co-authors
The 25 scholars most cited alongside Boris K. Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 50 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma Hit paper breakdown → | 2001 | 740 |
| 2 | Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Hit paper breakdown → | 2000 | 708 |
| 3 | The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae Hit paper breakdown → | 1990 | 582 |
| 4 | 2001 | 450 | |
| 5 | 2001 | 341 | |
| 6 | 2002 | 144 | |
| 7 | 2003 | 130 | |
| 8 | 2003 | 128 | |
| 9 | 2013 | 114 | |
| 10 | 2001 | 113 | |
| 11 | 2006 | 100 | |
| 12 | 1991 | 96 | |
| 13 | 2003 | 88 | |
| 14 | 2018 | 85 | |
| 15 | 2002 | 68 | |
| 16 | 2008 | 60 | |
| 17 | 2000 | 57 | |
| 18 | 2022 | 31 | |
| 19 | 2002 | 31 | |
| 20 | 2015 | 30 |
About Boris K. Lin
Boris K. Lin is a scholar working on Molecular Biology, Oncology, Hematology, Pathology and Forensic Medicine and Genetics, having authored 50 papers that have together received 4.4k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (15 papers), Lymphoma Diagnosis and Treatment (10 papers), Lung Cancer Treatments and Mutations (8 papers), Chronic Lymphocytic Leukemia Research (7 papers), PI3K/AKT/mTOR signaling in cancer (7 papers), Peptidase Inhibition and Analysis (7 papers), Cancer Mechanisms and Therapy (5 papers) and Protein Degradation and Inhibitors (4 papers). The work is most often cited by research in Hematology (2.4k citations), Oncology (1.6k citations), Genetics (543 citations), Molecular Biology (2.8k citations) and Pathology and Forensic Medicine (505 citations). Boris K. Lin has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Kenneth C. Anderson, Teru Hideshima, Dharminder Chauhan, Yu‐Tzu Tai, Faith E. Davies, Klaus Podar, Paul G. Richardson, Noopur Raje, George W. Muller and David Stirling. Their work appears in journals such as Blood, Journal of Clinical Oncology, Leukemia, Experimental Hematology and Molecular and Cellular Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.